Literature DB >> 25388838

Catalpol Inhibited the Proliferation of T24 Human Bladder Cancer Cells by Inducing Apoptosis Through the Blockade of Akt-Mediated Anti-apoptotic Signaling.

Di Jin1, Ming Cao1, Xin Mu1, Guoliang Yang1, Wei Xue1, Yiran Huang1, Haige Chen2.   

Abstract

Catalpol is an iridoid glucoside extracted from the traditional Chinese medicinal plant called Rehmannia glutinosa, and it is reported to possess a variety of pharmacological activities. The goal of this research was to explore the effect of catalpol on the human bladder cancer cells T24. The cells were treated for different durations with various concentrations of catalpol. Then the viability, mobility, and invasiveness of the cells were determined by MTT assay and flow cytometry, respectively. Catalpol was found to significantly suppress the proliferation, migration, and invasiveness of T24 bladder cancer cells in a dose- and time-dependent manner. The results also revealed that catalpol promoted apoptosis and caused the cell-cycle arrest at G2/M phase. Furthermore, the catalpol-mediated apoptosis was found to involve the modulation of PI3K/Akt pathway and inhibit the expression of anti-apoptotic B cell lymphoma-2 (Bcl-2) family proteins. Also, the expressions of Bcl-2 proapoptotic effectors, Bcl-2-associated X protein, and Bcl-2 associated death promoter were up-regulated in the cells treated with catalpol. The enzymes involved in the ultimate process of apoptosis, active caspase-3 and poly ADP ribose polymerase were elevated, and the latter was observed to be cleaved, indicating that catalpol-accelerated cell apoptosis involved a caspase-dependent pathway. These results suggest that catalpol might serve to be a promising therapeutic agent for the treatment of human bladder cancer.

Entities:  

Keywords:  Akt-mediated; Catalpol; Rehmannia glutinosa; T24 bladder cancer cells

Mesh:

Substances:

Year:  2015        PMID: 25388838     DOI: 10.1007/s12013-014-0355-0

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  8 in total

1.  Inhibitory effects of catalpol coordinated with budesonide and their relationship with cytokines and Interleukin-13 expression.

Authors:  Haibo Zhu; Hai Wang
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

2.  Nephrokeli, a Chinese herbal formula, may improve IgA nephropathy through regulation of the sphingosine-1-phosphate pathway.

Authors:  Yifei Zhong; Ke Wang; Xianwen Zhang; Xiaofan Cai; Yiping Chen; Yueyi Deng
Journal:  PLoS One       Date:  2015-01-29       Impact factor: 3.240

3.  The Impact of Catalpol on Proliferation, Apoptosis, Migration, and Oxidative Stress of Lung Cancer Cells Based on Nrf2/ARE Signaling.

Authors:  Huanyuan Wang; Jingtao Wu; Haiyin Fan; Yuan Ji; Chunbin Han; Chao Li; Sicong Jiang
Journal:  Biomed Res Int       Date:  2022-07-18       Impact factor: 3.246

4.  Anti-tumor effects of Atractylenolide I on bladder cancer cells.

Authors:  Rui Yu; Bi-Xia Yu; Jun-Feng Chen; Xiu-Yi Lv; Ze-Jun Yan; Yue Cheng; Qi Ma
Journal:  J Exp Clin Cancer Res       Date:  2016-03-01

5.  Efficacy, Safety, and Cost of Therapy of the Traditional Chinese Medicine, Catalpol, in Patients Following Surgical Resection for Locally Advanced Colon Cancer.

Authors:  Baogang Fei; Wei Dai; Shouhe Zhao
Journal:  Med Sci Monit       Date:  2018-05-15

6.  Eriocalyxin B Induces Apoptosis and Autophagy Involving Akt/Mammalian Target of Rapamycin (mTOR) Pathway in Prostate Cancer Cells.

Authors:  Ziqiang Yu; Yang Chen; Chaozhao Liang
Journal:  Med Sci Monit       Date:  2019-11-12

7.  Catalpol inhibits the proliferation, migration and metastasis of HCC cells by regulating miR‑140‑5p expression.

Authors:  Linsheng Wu; Haoxia Li; Shengyou Chen; Xiaoqiang Wu; Xiaomin Chen; Fangping Wang
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

8.  Catalpol ameliorates psoriasis-like phenotypes via SIRT1 mediated suppression of NF-κB and MAPKs signaling pathways.

Authors:  Aimin Liu; Buxin Zhang; Wei Zhao; Yuanhui Tu; Qingxing Wang; Jing Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.